Metformin is the standard first line treatment for Type 2 Diabetes, a disease that is expected to grow by 50% until 2030 worldwide and affect more than 500 million people. The global market for Metformin is expected to grow with a CAGR of 4-6% on an annual basis. Vistin Pharma is strategically well positioned to take part of this growth.
Vistin Pharma has the following product offerings:
Metformin HCl (API)
Metformin DC (direct compressible granules)
Customized Particle Distribution (PSD)
Our high quality Metformin is sold to well reputable international pharmaceutical companies
* Premix: Metformin + MgSt, can be delivered on-request